KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income: 2011-2024

Historic Other Non Operating Income for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$54.9 million.

  • Esperion Therapeutics' Other Non Operating Income fell 57.26% to $677,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $732,000, marking a year-over-year increase of 101.53%. This contributed to the annual value of -$54.9 million for FY2024, which is 1137.95% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Other Non Operating Income of -$54.9 million as of FY2024, which was down 1,137.95% from $5.3 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Other Non Operating Income registered a high of $5.3 million during FY2023, and its lowest value of -$54.9 million during FY2024.
  • Its 3-year average for Other Non Operating Income is -$15.7 million, with a median of $2.7 million in 2022.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 671.84% in 2021, then crashed by 1,137.95% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Other Non Operating Income stood at $515,000 in 2020, then surged by 671.84% to $4.0 million in 2021, then plummeted by 33.28% to $2.7 million in 2022, then skyrocketed by 99.51% to $5.3 million in 2023, then slumped by 1,137.95% to -$54.9 million in 2024.